{"generic":"Testolactone","drugs":["Teslac","Testolactone"],"mono":{"0":{"id":"ctbxs0","title":"Generic Names","mono":"Testolactone"},"1":{"id":"ctbxs1","title":"Dosing and Indications","sub":{"0":{"id":"ctbxs1b4","title":"Adult Dosing","mono":"<b>Breast cancer, Advanced or disseminated disease (as adjunct therapy during palliative treatment):<\/b> 250 mg ORALLY 4 times daily "},"1":{"id":"ctbxs1b5","title":"Pediatric Dosing","mono":"Safety and effectiveness in children not established"},"3":{"id":"ctbxs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Breast cancer, Advanced or disseminated disease (as adjunct therapy during palliative treatment)<br\/>"}}},"3":{"id":"ctbxs3","title":"Contraindications\/Warnings","sub":{"0":{"id":"ctbxs3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity to testolactone products<\/li><li>male breast cancer<\/li><\/ul>"},"2":{"id":"ctbxs3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},"3":{"id":"ctbxs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}}},"5":{"id":"ctbxs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema, Hypertension<\/li><li><b>Dermatologic:<\/b>Maculopapular eruption, Erythema<\/li><li><b>Gastrointestinal:<\/b>Glossitis, Loss of appetite, Nausea, Vomiting<\/li><li><b>Neurologic:<\/b>Paresthesia<\/li><li><b>Other:<\/b>Aching pain, Malaise<\/li><\/ul>"},"6":{"id":"ctbxs6","title":"Drug Name Info","sub":{"0":{"id":"ctbxs6b17","title":"US Trade Names","mono":"Teslac<br\/>"},"2":{"id":"ctbxs6b19","title":"Class","mono":"<ul><li>Androgen<\/li><li>Antineoplastic Agent<\/li><\/ul>"},"3":{"id":"ctbxs6b20","title":"Regulatory Status","mono":"Schedule III<br\/>"}}},"7":{"id":"ctbxs7","title":"Mechanism Of Action","mono":"Systemic: Testolactone is structurally similar to androgens but is not known to cause virilization. The mechanism of its antineoplastic activity is unknown, although it is reported to inhibit steroid aromatase activity (the effect may be noncompetitive and irreversible ) and reduce estrone synthesis from adrenal androstenedione (the major source of estrogen in postmenopausal women) .<br\/>"},"8":{"id":"ctbxs8","title":"Pharmacokinetics","sub":{"0":{"id":"ctbxs8b23","title":"Absorption","mono":"Systemic: Well absorbed<br\/>"},"2":{"id":"ctbxs8b25","title":"Metabolism","mono":"Systemic: Hepatic<br\/>"},"3":{"id":"ctbxs8b26","title":"Excretion","mono":"Systemic: Renal<br\/>"}}},"10":{"id":"ctbxs10","title":"Monitoring","mono":"<ul><li>evidence of tumor response<\/li><li>plasma calcium levels<\/li><\/ul>"},"12":{"id":"ctbxs12","title":"Toxicology","sub":[{"id":"ctbxs12b31","title":"Clinical Effects","mono":"<b>TESTOLACTONE<\/b><br\/>OVERDOSE: Limited overdose data. Effects are expected to be an extension of adverse effects reported with therapeutic use. ADVERSE EFFECTS: Maculopapular erythema, hypertension, paresthesia, malaise, aching pain, edema of the extremities, glossitis, anorexia, N\/V, alopecia (rare), nail growth disturbance (rare).<br\/>"},{"id":"ctbxs12b32","title":"Treatment","mono":"<b>TESTOLACTONE<\/b><br\/><ul><li>Decontamination: Decontamination is generally not necessary; consider activated charcoal after very large ingestions or if more toxic coingestants involved.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Monitoring of patient: Vital signs, fluids and electrolytes status patients with significant vomiting.<\/li><\/ul>"},{"id":"ctbxs12b33","title":"Range of Toxicity","mono":"<b>TESTOLACTONE<\/b><br\/>TOXICITY: A specific toxic dose has not been delineated. ADULT THERAPEUTIC DOSE: 250 mg four times daily. <br\/>"}]},"13":{"id":"ctbxs13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause edema, maculopapular eruption, erythema, glossitis, anorexia, nausea, vomiting, paresthesia, aching pain, and malaise.<\/li><li>Advise patient to call healthcare professional if a treatment is missed, as drug should be given on a regular schedule.<\/li><\/ul>"}}}